Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial

Abstract Background We aimed to evaluate the effect of cranberry supplementation on serum liver enzymes, hepatic steatosis, and cardiometabolic risk factors in patients with non-alcoholic fatty liver (NAFLD). Methods In the present parallel-designed randomized controlled clinical trial, 110 patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kourosh Masnadi Shirazi, Elham Shirinpour, Arman Masnadi Shirazi, Zeinab Nikniaz
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Cranberry NAFLD Cardiometabolic Liver enzymes Other systems of medicine RZ201-999
Acceso en línea:	https://doaj.org/article/956c39cdc26547f48cd907d9cb8bca65
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:956c39cdc26547f48cd907d9cb8bca65
record_format	dspace
spelling	oai:doaj.org-article:956c39cdc26547f48cd907d9cb8bca652021-11-21T12:39:50ZEffect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial10.1186/s12906-021-03436-62662-7671https://doaj.org/article/956c39cdc26547f48cd907d9cb8bca652021-11-01T00:00:00Zhttps://doi.org/10.1186/s12906-021-03436-6https://doaj.org/toc/2662-7671Abstract Background We aimed to evaluate the effect of cranberry supplementation on serum liver enzymes, hepatic steatosis, and cardiometabolic risk factors in patients with non-alcoholic fatty liver (NAFLD). Methods In the present parallel-designed randomized controlled clinical trial, 110 patients with NAFLD were enrolled. The patients were randomized to receive 144 mg cranberry capsule or placebo for 6 months. The primary efficacy of the treatment was lipid profile, glycemic measurements, and liver enzyme levels. Results The data were reported for 46 in the supplementation group and 48 in the placebo group. The patient’s mean (SD) age was 43.16 (11.08) years. No significant differences between groups were observed regarding the post-intervention level of liver enzyme. The mean after-intervention levels of total cholesterol (p < 0.001) and triglyceride (p = 0.01) were significantly lower in the intervention group compared with the placebo group. At the end of the study, the mean insulin and HOMA-IR levels were significantly lower in the cranberry group compared with the placebo group. Significantly more patients in the cranberry group experienced a decrease in steatosis level compared with the control group. Conclusion The results of the present study showed that cranberry supplementation had a positive effect on some lipid profiles, insulin resistance, and hepatic steatosis in patients with NAFLD. Trial registration IRCT20200725048200N1 ; first registration date: 11.8.2020.Kourosh Masnadi ShiraziElham ShirinpourArman Masnadi ShiraziZeinab NikniazBMCarticleCranberryNAFLDCardiometabolicLiver enzymesOther systems of medicineRZ201-999ENBMC Complementary Medicine and Therapies, Vol 21, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cranberry NAFLD Cardiometabolic Liver enzymes Other systems of medicine RZ201-999
spellingShingle	Cranberry NAFLD Cardiometabolic Liver enzymes Other systems of medicine RZ201-999 Kourosh Masnadi Shirazi Elham Shirinpour Arman Masnadi Shirazi Zeinab Nikniaz Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial
description	Abstract Background We aimed to evaluate the effect of cranberry supplementation on serum liver enzymes, hepatic steatosis, and cardiometabolic risk factors in patients with non-alcoholic fatty liver (NAFLD). Methods In the present parallel-designed randomized controlled clinical trial, 110 patients with NAFLD were enrolled. The patients were randomized to receive 144 mg cranberry capsule or placebo for 6 months. The primary efficacy of the treatment was lipid profile, glycemic measurements, and liver enzyme levels. Results The data were reported for 46 in the supplementation group and 48 in the placebo group. The patient’s mean (SD) age was 43.16 (11.08) years. No significant differences between groups were observed regarding the post-intervention level of liver enzyme. The mean after-intervention levels of total cholesterol (p < 0.001) and triglyceride (p = 0.01) were significantly lower in the intervention group compared with the placebo group. At the end of the study, the mean insulin and HOMA-IR levels were significantly lower in the cranberry group compared with the placebo group. Significantly more patients in the cranberry group experienced a decrease in steatosis level compared with the control group. Conclusion The results of the present study showed that cranberry supplementation had a positive effect on some lipid profiles, insulin resistance, and hepatic steatosis in patients with NAFLD. Trial registration IRCT20200725048200N1 ; first registration date: 11.8.2020.
format	article
author	Kourosh Masnadi Shirazi Elham Shirinpour Arman Masnadi Shirazi Zeinab Nikniaz
author_facet	Kourosh Masnadi Shirazi Elham Shirinpour Arman Masnadi Shirazi Zeinab Nikniaz
author_sort	Kourosh Masnadi Shirazi
title	Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial
title_short	Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial
title_full	Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial
title_fullStr	Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial
title_full_unstemmed	Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial
title_sort	effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with nafld: a randomized clinical trial
publisher	BMC
publishDate	2021
url	https://doaj.org/article/956c39cdc26547f48cd907d9cb8bca65
work_keys_str_mv	AT kouroshmasnadishirazi effectofcranberrysupplementationonliverenzymesandcardiometabolicriskfactorsinpatientswithnafldarandomizedclinicaltrial AT elhamshirinpour effectofcranberrysupplementationonliverenzymesandcardiometabolicriskfactorsinpatientswithnafldarandomizedclinicaltrial AT armanmasnadishirazi effectofcranberrysupplementationonliverenzymesandcardiometabolicriskfactorsinpatientswithnafldarandomizedclinicaltrial AT zeinabnikniaz effectofcranberrysupplementationonliverenzymesandcardiometabolicriskfactorsinpatientswithnafldarandomizedclinicaltrial
_version_	1718418899799638016

Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial

Ejemplares similares